作者
Nathalie A Kulin, Anne Pastuszak, Suzanne R Sage, Betsy Schick-Boschetto, Glenda Spivey, Marcia Feldkamp, Kelly Ormond, Doreen Matsui, Amy K Stein-Schechman, Lola Cook, Joanne Brochu, Michael Rieder, Gideon Koren
发表日期
1998/2/25
期刊
Jama
卷号
279
期号
8
页码范围
609-610
出版商
American Medical Association
简介
Context
Although a large number of women of reproductive age use new selective serotonin reuptake inhibitors (SSRIs) and half of all pregnancies are unplanned, no data exist on the safety of these agents for the human fetus.
Objective
To assess fetal safety and risk of fluvoxamine, paroxetine, and sertraline.
Design
A prospective, multicenter, controlled cohort study.
Setting
Nine Teratology Information Service centers in the United States and Canada.
Patients
All women who were counseled during pregnancy following exposure to a new SSRI and followed up by the participating centers. Controls were randomly selected from women counseled after exposure to nonteratogenic agents.
Main Outcome Measures
Rates of major congenital malformations.
Results
A total of 267 women exposed to an SSRI and 267 controls were studied. Exposure to SSRIs was not associated with either increased risk for major malformations …
引用总数
学术搜索中的文章
NA Kulin, A Pastuszak, SR Sage, B Schick-Boschetto… - Jama, 1998
